Catalyst Biosciences, Inc. (NASDAQ:CBIO) Traded Higher Than Its 50 Day Average

0
30

The stock last traded at $4.90 a tad higher than the 50 day moving average which is $4.64 and which is well above the 200 day moving average of $4.38. The 50 day moving average was up $0.26 or +5.54% and the 200 day average went up by +11.88%. (NASDAQ:CBIO) shares saw light trading volume with 311 shares changing hands by the end of trading on Tuesday. Volume was down 99.98% under the stocks average daily volume.

Short traders are feeling a little more bearish on Catalyst Biosciences, Inc. recently looking at the change in short interest. The firm realized a rise in short interest between September 15, 2017 and September 29, 2017 of 4.80%. Short shares increased 25,162 over that period. With short interest at 549,463 and short average daily volume at 239,752, the short-interest ratio is 2.0 and the percentage of shorted shares is 0.14% as of September 29.

As of the latest earnings report the EPS was $-14.07 and is estimated to be $-7.91 for the current year with 4,310,000 shares currently outstanding. Next quarter’s EPS is estimated at $-1.55 and the next full year EPS is anticipated to be $-4.81.

Catalyst Biosciences, Inc., formerly Targacept, Inc., launched on March 7, 1997, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Business’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development..